Corporate Banner
Satellite Banner
Technology Networks Header
Sunday, April 20, 2014
Technology Networks
 
Register | Sign in
Home Page > Videos > Epigenetic Variation as a Driver of Breast Cancer Risk
  Videos

Return

Epigenetic Variation as a Driver of Breast Cancer Risk
Imperial College London

Genetic epidemiology aims to use the natural variation in the genome to look for associations between particular genotypes and disease risk or prognosis. Epigenetic epidemiology, a new area of research, aims to address the same questions about disease risk and prognosis using the natural variation present in the epigenome. It is now apparent that the variation between individuals does not occur at the classical promoter CpG island, but in other areas of the gene and that these regions are yielding markers of both cancer risk and prognosis. We have identified a breast cancer risk marker in the ATM gene using blood samples collected from prospective cohorts. We have also analysed blood samples from an ovarian cancer clinical trial, SCOTROC1, to identify prognostic biomarkers of progression free survival, overall survival, response and toxicity. Lastly, we have also shown that cancer risk exposures, such as smoking, can affect the epigenome detectable in blood DNA and may provide a more accurate measure of long term exposures. These studies, therefore, support the hypothesis that epigenetic variation may be a driver of cancer risk or prognosis.

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Domainex Programme Shows Great Promise for the Treatment of Inflammatory Diseases
Company’s IKKe/TBK1 programme to offer a disease-modifying treatment for COPD patients.
Drug Does Not Improve Set of Cardiovascular Outcomes for Diastolic Heart Failure
NIH-supported study finds drug does appear to reduce hospitalizations for diastolic heart failure.
Blocking DNA Repair Mechanisms Could Improve Brain Cancer Therapy
The findings were published April 7 in Nature Communications.
Aspirin Does Not Prevent Pregnancy Loss, NIH Study Finds
Increased live birth rate in subgroup of participants.
Statins Slow the Progression of Advanced MS in Clinical Trial
The work is published in the Lancet.
Researchers Discover Underlying Genetics, Marker for Stroke, Cardiovascular Disease
NIH-funded findings point to new potential strategies for disease prevention, treatment.
New Clinical Study on the Relationship Between Imaging and OVA1®
New analysis explores interactions between clinical risk factors used in pre-surgical assessment.
Statins Slow the Progression of Advanced MS in Clinical Trial
The work is published in the Lancet.
Sepsis Study Comparing Three Treatment Methods Shows Same Survival Rate
NIH-funded clinical trial tested specific protocols against usual high-level care.
New Trial of Personalized Cancer Treatment Begins in Oxford
Phase I trial in Oxford will investigate a new drug, called CXD101.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv